Busulfan and Fludarabine as Conditioning for Allogeneic Stem Cell Transplantation: a Pharmacokinetic Study
NCT00156858 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2012-01-19
Summary
A study of pharmacokinetics of daily intravenous busulfan
Conditions
- Hematologic Malignancy
Interventions
- DRUG
-
intravenous busulfan
Sponsors & Collaborators
-
Alberta Health services
lead OTHER
Principal Investigators
-
James Russell, FRCp · Alberta Cancerboard
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 1998-01-31
- Completion
- 2010-12-31
Countries
- Canada
Study Locations
More Related Trials
-
Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation
NCT01643668 ·Status: COMPLETED ·Phase: PHASE2
-
Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies
NCT02129582 ·Status: COMPLETED ·Phase: PHASE1
-
Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning
NCT01572662 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
NCT00469014 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance
NCT01702831 ·Status: COMPLETED ·Phase: PHASE2
-
Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
NCT00245037 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML
NCT01191957 ·Status: COMPLETED ·Phase: PHASE3
-
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
NCT01366612 ·Status: TERMINATED ·Phase: PHASE3
-
Busulfan and Fludarabine Before Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer
NCT00301912 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation
NCT01596699 ·Status: TERMINATED ·Phase: PHASE2
-
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
NCT02861417 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI)
NCT00815568 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen
NCT00556452 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases
NCT00582894 ·Status: COMPLETED ·Phase: NA
-
Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor
NCT00582933 ·Status: COMPLETED ·Phase: PHASE2
-
Imatinib Mesylate, Busulfan, Fludarabine, and Antithymocyte Globulin for CML Patients
NCT00499889 ·Status: TERMINATED ·Phase: PHASE2
-
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
NCT02328950 ·Status: UNKNOWN
-
Sequential and Personalized PK-guided Busulfan Administration in the Frame of the Conditiong Regimen for Allo-HSCT in Patients With Malignant Hemopathies Ineligible for the Standard Myeloablative Conditioning
NCT04451200 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies
NCT01056614 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)
NCT00598624 ·Status: UNKNOWN ·Phase: PHASE2
-
The Optimization of Conditioning Regimen for HLA Matched HSCT in SAA
NCT06069180 ·Status: RECRUITING ·Phase: PHASE4
-
Study of a Reduced-toxicity "Submyeloablative" Conditioning Regimen Prior to Allogeneic Stem Cell Transplantation in Patients With Hematological Malignancies
NCT00841724 ·Status: COMPLETED ·Phase: PHASE2
-
Pharmacokinetic Study of Busulfan in Allogeneic Stem Cell Transplantation in Adult Patients With Acute Leukemia
NCT01498016 ·Status: UNKNOWN ·Phase: PHASE2
-
Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide
NCT00800839 ·Status: COMPLETED ·Phase: PHASE2
-
Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer
NCT00346359 ·Status: COMPLETED ·Phase: PHASE2